Trial · NCT02431702
Participant flow63
How many started, completed or left each group, period by period.
41 to 60 of 63
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 2: 9Month Disease Progression Phase | NOT COMPLETED | Part 3-OAP to OAP (EDP and Disease Modification) | 0 | |
| Part 2: 9Month Disease Progression Phase | NOT COMPLETED | Healthy Controls | 0 | |
| Part 3: 9 Month of Additional Treatment | STARTED | Part 1-Run-in: Oral Antipsychotics (OAP) | 0 | |
| Part 3: 9 Month of Additional Treatment | STARTED | Part 2-Paliperidone Palmitate (PP) | 0 | |
| Part 3: 9 Month of Additional Treatment | STARTED | Part 2-OAP | 0 | |
| Part 3: 9 Month of Additional Treatment | STARTED | Part 3-PP to PP (Extended Disease Progression [EDP] and Disease Modification) | 49 | |
| Part 3: 9 Month of Additional Treatment | STARTED | Part 3- OAP to PP (or Delayed-Start PP) (Disease Modification) | 57 | |
| Part 3: 9 Month of Additional Treatment | STARTED | Part 3-OAP to OAP (EDP and Disease Modification) | 63 | |
| Part 3: 9 Month of Additional Treatment | STARTED | Healthy Controls | 0 | |
| Part 3: 9 Month of Additional Treatment | COMPLETED | Part 1-Run-in: Oral Antipsychotics (OAP) | 0 | |
| Part 3: 9 Month of Additional Treatment | COMPLETED | Part 2-Paliperidone Palmitate (PP) | 0 | |
| Part 3: 9 Month of Additional Treatment | COMPLETED | Part 2-OAP | 0 | |
| Part 3: 9 Month of Additional Treatment | COMPLETED | Part 3-PP to PP (Extended Disease Progression [EDP] and Disease Modification) | 40 | |
| Part 3: 9 Month of Additional Treatment | COMPLETED | Part 3- OAP to PP (or Delayed-Start PP) (Disease Modification) | 47 | |
| Part 3: 9 Month of Additional Treatment | COMPLETED | Part 3-OAP to OAP (EDP and Disease Modification) | 46 | |
| Part 3: 9 Month of Additional Treatment | COMPLETED | Healthy Controls | 0 | |
| Part 3: 9 Month of Additional Treatment | NOT COMPLETED | Part 1-Run-in: Oral Antipsychotics (OAP) | 0 | |
| Part 3: 9 Month of Additional Treatment | NOT COMPLETED | Part 2-Paliperidone Palmitate (PP) | 0 | |
| Part 3: 9 Month of Additional Treatment | NOT COMPLETED | Part 2-OAP | 0 | |
| Part 3: 9 Month of Additional Treatment | NOT COMPLETED | Part 3-PP to PP (Extended Disease Progression [EDP] and Disease Modification) | 9 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02431702/flow?page=3